All In Biotech

Drug Trial Radar · NCT05723588

Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 31, 2023

Primary completion

Nov 1, 2027

Study completion Nov 1, 2027

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
First posted
Feb 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tobacco use is the number one preventable cause of the death in the United States, and is high among US Veterans, and those who have experienced trauma are more likely to smoke. Despite the efficacy of current evidence-based treatments for smoking cessation, there is a critical need for alternative treatments. This project seeks to evaluate the feasibility and effectiveness of a smoking cessation treatment for Veterans with posttraumatic stress disorder (PTSD) who smoke. The treatment combines smoking cessation counseling, nicotine replacement therapy (e.g., nicotine gum), and repetitive transcranial magnetic stimulation (rTMS). rTMS is a noninvasive brain stimulation treatment that has been cleared by the Food and Drug Administration for smoking cessation in adults.

Conditions

  • Tobacco Use Disorder

Interventions

  • active repetitive transcranial magnetic stimulationDevice

    Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.

  • sham repetitive transcranial magnetic stimulationDevice

    Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.

  • cognitive behavioral therapy for smoking cessationBehavioral

    All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.

  • nicotine replacement therapyDrug

    All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a "rescue" method such as nicotine lozenge or nicotine gum.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility as measured by number of participants recruitedTime frame: At consent
  2. Feasibility as measured by the percent of participants who complete the studyTime frame: 3-month follow-up
  3. Number of participants with self-reported and bioverified abstinence from smokingTime frame: End of treatment, about five weeks after beginning study
  4. Number of participants with self-reported and bioverified abstinence from smokingTime frame: 3-month follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Durham VA Medical Center, Durham, NC

    Durham, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.